Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21476018 | 0.82 | PTGS2 (0.45) | PTGS2FAAHMGLLLMNA | |
| SCHEMBL15131097 | 0.81 | PTGS2 (0.44) | PTGS2FAAHMGLLGABRA1GABRB2 | |
| SCHEMBL19539301 | 0.80 | PTGS2 (0.35) | PTGS2 | |
| SCHEMBL13145784 | 0.77 | FAAH (0.41) | PTGS2FAAHMGLLGABRA1GABRB2 | |
| SCHEMBL1106452 | 0.77 | PTGS2 (0.39) | PTGS2MGLLLMNACA2CYP1A2 | |
| SCHEMBL18368383 | 0.76 | TSHR (0.36) | PTGS2FAAHMGLLGABRA1GABRB2 | |
| SCHEMBL23029070 | 0.75 | FAAH (0.40) | PTGS2FAAHMGLLGABRA1GABRB2 | |
| SCHEMBL10883824 | 0.75 | DAO (0.42) | PTGS2FAAHMGLLGABRA1GABRB2 | |
| SCHEMBL21764022 | 0.75 | FAAH (0.40) | PTGS2FAAHMGLLGABRA1GABRB2 | |
| SCHEMBL9453847 | 0.75 | PTGS2 (0.41) | PTGS2GABRA1GABRB2LMNACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002308-A1 | AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2022-01-06 | — | — | US | disclosed |
| US-10966985-B2 | Macrocyclic compounds as ROS1 kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2021022061-A1 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | OREGON STATE UNIVERSITY (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20200385386-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS AND USES THEREOF | ANGEX PHARMACEUTICAL, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200291026-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2020-09-17 | — | — | US | disclosed |
| US-10647711-B2 | Azepin-2-one derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10647730-B2 | Macrocyclic compounds as TRK kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190151322-A1 | MACROCYCLIC COMPOUNDS AS ROS1 KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-05-23 | — | — | US | disclosed |
| US-20190152968-A1 | AZEPIN-2-ONE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-20190031684-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-01-31 | — | — | US | disclosed |
| US-20110313156-A1 | HETEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110313156-A1 | HETEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20100234352-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234352-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100183513-A1 | N-(METHYL) -1H-PYRAZOL-3-AMINE, N-(METHYL)-PYRIDIN-2-AMINE AND N-(METHYL)-THIAZOL-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | AC IMMUNE SA (CH) | 2010-07-22 | — | — | US | disclosed |
| US-7696352-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070185092-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070185092-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185092-A1 | FACTOR Xa INHIBITORS | TFPI, F12, F11 | PTGS2 885/4885FAAH 498/4885MGLL 1572/4885 |
| US-20200291026-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | PTGS2 3317/4885FAAH 3962/4885MGLL 4023/4885 |
| US-20190031684-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | PTGS2 2850/4885FAAH 3865/4885MGLL 4092/4885 |
| US-20100183513-A1 | N-(METHYL) -1H-PYRAZOL-3-AMINE, N-(METHYL)-PYRIDIN-2-AMINE AND N-(METHYL)-THIAZOL-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | PSEN2, APP, PSEN1 | PTGS2 162/4885FAAH 3124/4885MGLL 3303/4885 |
| US-20200385386-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS AND USES THEREOF | MAP3K20, PNCK, CDC42BPG | PTGS2 4633/4885FAAH 4342/4885MGLL 2834/4885 |
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | PTGS2 1023/4885FAAH 392/4885MGLL 1868/4885 |
| US-20190152968-A1 | AZEPIN-2-ONE DERIVATIVES AS RSV INHIBITORS | AZI2, FURIN, ACE2 | PTGS2 579/4885FAAH 1801/4885MGLL 3583/4885 |
| US-20110313156-A1 | HETEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS | PDK2, PDK4, CCNH | PTGS2 2235/4885FAAH 1271/4885MGLL 892/4885 |
| US-10966985-B2 | Macrocyclic compounds as ROS1 kinase inhibitors | ROS1, MAP3K1, MAP3K19 | PTGS2 3452/4885FAAH 4847/4885MGLL 4590/4885 |
| US-20220002308-A1 | AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | MERTK, AXL, TYRO3 | PTGS2 3905/4885FAAH 3219/4885MGLL 3631/4885 |
| US-10647711-B2 | Azepin-2-one derivatives as RSV inhibitors | AZI2, FURIN, ACE2 | PTGS2 579/4885FAAH 1801/4885MGLL 3583/4885 |
| US-20100234352-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | PTGS2 885/4885FAAH 498/4885MGLL 1572/4885 |
| US-10647730-B2 | Macrocyclic compounds as TRK kinase inhibitors | MAP3K20, MAP3K1, MAP3K3 | PTGS2 2850/4885FAAH 3865/4885MGLL 4092/4885 |
| US-20190151322-A1 | MACROCYCLIC COMPOUNDS AS ROS1 KINASE INHIBITORS | ROS1, MAP3K1, MAP3K19 | PTGS2 3452/4885FAAH 4847/4885MGLL 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.